News & Updates

Boys who were exposed to screens for longer hours at 1 year of age have significantly increased risk of having autism spectrum disorder (ASD) at 3 years of age, suggest data from the The Japan Environment and Children’s Study.

In the treatment of patients with severe retinopathy of prematurity (ROP), laser appears to increase the trend to severe myopia, according to a study. Meanwhile, intravitreal bevacizumab does not affect myopic progression and reduces the need to consequently undergo laser treatment.

A diet low in cholesterol and saturated fatty acids, initiated and maintained from infancy, seems to improve cognitive flexibility and inhibitory control at young adulthood, reports a new study.

New drug applications approved by US FDA as of 16-31 March 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

E-cigarette use, whether current or previous, is prevalent among adolescents with asthma, according to the results of a meta-analysis.

Prenatal ultrasound in the second trimester appears to detect anomalies in the heart, kidneys, and head common in foetuses who are likely to develop autism spectrum disorder, according to a study.

While the mRNA vaccines currently available on the market have gained regulatory nods* for use in children aged 5 or 6 years old**, Moderna’s mRNA-1273 vaccine is setting a “new low” by showing that two 25 μg doses of the vaccine induce a robust immune response in infants/children as young as 6 months to <6 years of age, according to the latest data from the KidCOVE study.

The primary repair (PR) approach to managing neonates with symptomatic tetralogy of Fallot (sTOF) results in lower costs than that for staged repair (SR), a study has shown.

Infants with early vitamin B12 deficiency commonly show signs of spells, tremors, and irritability, a new study has found. The administration of nitrous oxide during labour appears to be a risk factor for such deficiency in neonates.

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.